Synnovation Therapeutics
Manufacturing · Delaware, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
200 Powder Mill Rd, Wilmington, Delaware...Phone Number
(302) 521-9490Website
www.synnovationtx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Synnovation Therapeutics
Synnovation is focused on the discovery and development of best-in-class targeted medicines aimed at improving patient lives. The company utilizes its expertise in biology and a skilled medicinal chemistry team to create a diverse pipeline of novel small molecule therapies. Their mission is to advance these therapeutics into clinical trials efficiently, with an emphasis on patient-focused precision medicine. Synnovation targets healthcare providers and patients seeking innovative treatment options.Explore more
Synnovation Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Synnovation Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Synnovation Therapeutics launches new products
Check out if Synnovation Therapeutics is spiking on competitors!
Check if Synnovation Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Synnovation Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Synnovation Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Synnovation Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Synnovation Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Synnovation Therapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined Synnovation Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Synnovation Therapeutics
Compare insights from companies similar to Synnovation Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Synnovation Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Synnovation Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Synnovation Therapeutics.
Synnovation Therapeutics financials insights
Gather financial insights about Synnovation Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Other Financing Round
$69.9M
Synnovation Therapeutics Tech Stack
A closer look at the technologies used by Synnovation Therapeutics
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Synnovation Therapeutics News & Media
Synnovation Therapeutics Announces the Appointment of Rafael G. Amado, M.D., to Its Board of Directors
WILMINGTON, Del.--(BUSINESS WIRE)--Synnovation Therapeutics, a precision medicine company focused on the discovery and development of best-in-class targeted medicines, today announced the appointment of Rafael G. Amado, M.D., as a new member of its Board of Directors. “On behalf of the Synnovation Board of Directors, I am excited to welcome Rafael,” said Wenqing Yao, Founder and Chief Executive Officer of Synnovation. “He has consistently demonstrated a strong commitment to scientific excellencSynnovation Therapeutics Announces Second Program to Enter the Clinic: First Patient Dosed in Phase I Trial with SNV4818, a Potential Best-In-Class Pan-Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors
WILMINGTON, Del.--(BUSINESS WIRE)--Synnovation Therapeutics, a precision medicine company focused on the discovery and development of best-in-class targeted medicines, today announced that the first patient has been dosed in a Phase I trial evaluating SNV4818 as a monotherapy and in combination with fulvestrant, in patients with breast cancer and other solid tumors. SNV4818 is a potentially best-in-class pan-mutant-selective PI3Kα inhibitor that may effectively cover kinase (H), helical domainSynnovation Therapeutics announces its plans to double down on Delaware
Bronze Valley VentureLab puts out its latest cohort of up-and-coming startups, CAFE hires a new program manager, and more of Delaware’s biggest moves.Synnovation Therapeutics Announces First Patient Dosed in Phase I Trial with SNV1521, a PARP1 Selective Inhibitor for the Treatment of Solid Tumors
WILMINGTON, Del.--(BUSINESS WIRE)--Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, today announced that the first patient has been dosed in a Phase I trial evaluating SNV1521 in patients with solid tumors. SNV1521 is a potentially best-in-class, potent, highly selective and CNS penetrant PARP1 inhibitor. The Phase I trial, which is being led by Timothy Yap, M.D.,
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Synnovation Therapeutics
Sign Up For FreeTo access detailed company insights
Synnovation is focused on the discovery and development of best-in-class targeted medicines aimed at improving patient lives. The company utilizes its expertise in biology and a skilled medicinal chemistry team to create a diverse pipeline of novel small molecule therapies. Their mission is to advance these therapeutics into clinical trials efficie... Read More
